Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
b-cell activating factor receptor chimeric antigen receptor t-cell (Mayo Clinic)
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
MC10029 (BAFFR CAR-T) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell activating factor receptor (BAFF-R), a member of the tumor necrosis factor receptor superfamily essential for B-cell survival and maturation. Developed by the Mayo Clinic, the therapy involves engineering a patient's own T cells using a lentiviral vector to express a CAR construct containing an scFv derived from a novel anti-BAFF-R monoclonal antibody. BAFF-R is consistently expressed on malignant B cells, including those that have lost CD19 expression, making MC10029 a potential treatment for patients with relapsed or refractory B-cell malignancies who have failed CD19-targeted therapies. It is currently being evaluated in Phase 1 clinical trials (NCT06191887) for conditions such as chronic lymphocytic leukemia (CLL) and other B-cell hematologic malignancies.
- Other names
- BAFFR CAR-TBAFF-R CAR-TB-cell activating factor receptor chimeric antigen receptor T-cell
02
Targets
TNFRSF13C (B-cell Activating Factor Receptor)
Beyond the preview
Go deeper on b-cell activating factor receptor chimeric antigen receptor t-cell (Mayo Clinic).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on b-cell activating factor receptor chimeric antigen receptor t-cell (Mayo Clinic).